Ipsen halts development of Albireo's liver disease candidate ritivixibat after a $952 million acquisition
R&D pipeline's sweeping restructuring
French pharmaceutical company Ipsen (IPN) announced that, following its 2023 acquisition of Albireo Pharma for $952 million, it will discontinue or suspend R&D on two liver‑disease candidates it obtained in the deal. The program that has been fully terminated is ritivixibat (A3907), an Ileal Bile Acid Transporter (IBAT) inhibitor that was being evaluated in a Phase 2 trial (NCT05642468) for the rare chronic condition Primary Sclerosing Cholangitis (PSC). Ipsen cited severe difficulty enrolling patients and terminated the study early, relinquishing all rights to the asset. A second candidate, A2342, which targets the protein responsible for transporting bile acids into cells, completed Phase 1 but was removed from the pipeline without further clinical development.
The true value of Bylvay, the deal's core asset
Although the anticipated pipeline synergies from the Albireo acquisition have diminished, the deal’s cornerstone product, Bylvay (generic name odevixibat), remains a central growth driver for Ipsen. Bylvay, already approved for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS), is projected to generate €180 million (approximately $231.6 million) in global sales in 2025. Rather than allocating R&D funds to early‑stage assets with uncertain value, Ipsen has decided to concentrate resources on expanding Bylvay’s approved indications, notably by pursuing a Phase 3 trial in Biliary Atresia (NCT04336722).
Ipsen’s early termination of the ritivixibat Phase 2 PSC trial and the abandonment of A2342 R&D accelerate the write‑down of early‑stage assets acquired in the $952 million Albireo deal, improving short‑term R&D efficiency. This creates an immediate shift in the PSC market—estimated at $188.4 million in 2026—where Mirum Pharmaceuticals is gaining a competitive edge with volixibat, which recently reported positive itch‑relief data in Phase 2 and is now pursuing FDA approval. In the longer term, Ipsen can redirect its organization toward Bylvay, which recorded $231.6 million in annual sales in 2025, and focus on the Phase 3 Biliary Atresia indication. The move also eliminates the need to fund additional milestones and ongoing trial costs for the discontinued programs, preserving cash flow and avoiding the contingent payment of up to $227 million tied to a future FDA approval of Bylvay for Biliary Atresia. Overall, this portfolio optimization reflects the broader industry trend among rare‑disease specialists to prioritize commercially viable assets over uncertain early‑stage pipelines, enforcing a more conservative allocation of R&D capital.
Source: FierceBiotech (rss)